Kovalent

Kovalent is a biotechnology company focused on the discovery and development of next-generation covalent small molecule inhibitors for high-value, difficult-to-drug targets. The company leverages a proprietary platform that integrates chemical biology, structural biology, and computational chemistry to identify and optimize covalent binders with high selectivity and potency. Kovalent's primary focus areas include oncology and immunology, where covalent inhibition can provide significant advantages in overcoming drug resistance and achieving prolonged target engagement. Led by industry veterans and pioneers in covalent chemistry, the company aims to expand the reach of small molecule drugs to previously inaccessible therapeutic targets. By systematically mapping nucleophilic residues across the proteome, Kovalent is building a robust pipeline of precision medicines designed to address significant unmet medical needs.